This study presents direct neuropathological evidence from humans that oligomeric tau accumulates at synapses in Alzheimer's disease (AD), supporting a trans-synaptic model of tau propagation.

Utilizing high-resolution array tomography and immunoelectron microscopy on postmortem human cortex (focusing on temporal and occipital regions), the authors show that oligomeric tau species are present in both pre- and postsynaptic compartments in AD brains, while largely absent in age-matched controls. Notably, synaptic oligomeric tau is observed even in regions lacking dense fibrillar tau pathology, suggesting that this is an early process that is spatially dissociated from classic neurofibrillary tangles.

In comparison to other tau conformations (such as phosphorylated or misfolded tau), oligomeric tau is preferentially enriched at synapses. This supports experimental models that indicate soluble tau species—not fibrils—as the main mediators of synaptic toxicity. The presence of tau on both sides of the synapse bolsters the hypothesis that tau spreads trans-synaptically, contributing to the progression of the disease within neural networks.

Clinical and Translational Implications:

• Synaptic dysfunction in AD may be primarily driven by soluble oligomeric tau, rather than solely by the burden of fibrillar tau.

• Tau pathology likely initiates at the synaptic level before significant regional neurodegeneration occurs, which may explain early cognitive decline that happens prior to heavy tangle deposition.

• Therapeutic approaches targeting oligomeric tau species or synaptic tau trafficking might be more effective than those focusing solely on clearing fibrillar tau.

• These findings support a network-centric perspective of AD progression, aligning with clinical patterns of cognitive decline spreading in steps.

Bottom line:
This research offers strong human evidence that synaptic oligomeric tau is an early pathogenic agent in AD and a likely substrate for trans-neuronal spread, making it a prime target for disease-modifying therapies.